Chaoju Eye Care Holdings Limited (“Chaoju Eye Care”, Stock Code: 02219.HK) completed its listing on the Main Board of the Hong Kong Stock Exchange on July 7, 2021. Chaoju Eye Care offered 171 million shares globally at HKD 10.6 per share, among which 85.465 million shares are under the Hong Kong Public Offering and the remaining 85.465 million shares are for International Placing. It is supposed to raise approximately HKD 1.357 billion net proceeds from the global offering.

Chaoju Eye Care is a leading ophthalmic medical service group in North China with a strong reputation nationwide. Founded in 1988, the company has established an extensive network of ophthalmic hospitals and optical centers across the Inner Mongolia Autonomous Region, Zhejiang Province, Jiangsu Province, Shanxi Province and Hebei Province. Chaoju Eye Care operates 17 ophthalmic hospitals, 23 optical centers and 2 clinics. According to the report released by Frost & Sullivan, Chaoju Eye Care ranked first in Inner Mongolia, second in North China and fifth in China among private ophthalmic hospitals in terms of revenues in 2020. 

As the Chinese legal adviser to the issuer, Jingtian & Gongcheng’s legal team provided one-stop, end-to-end legal services for the listing of Chaoju Eye Care, including assisting in the design of the domestic and overseas restructuring architecture, conducting thorough Chinese legal due diligence, analyzing and resolving critical legal issues, the issuing of legal opinions, assisting in answering multiple rounds of inquiries from the Stock Exchange of Hong Kong. The team is highly trusted and recognized by the client for its strict work attitude as well as effective and timely legal services.